The Benchmark Company initiated coverage on Trillium Therapeutics with a new price target

4/14/21 7:33:47 AM ET

Major Pharmaceuticals

Health Care

The Benchmark Company initiated coverage of Trillium Therapeutics with a rating of Buy and set a new price target of $21.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRIL

Date	Price Target	Rating	Analyst
11/17/2021		Buy → Hold	The Benchmark Company
11/17/2021		Buy → Hold	Benchmark
8/24/2021	$21.00 → $18.50	Buy → Hold	Craig-Hallum
8/24/2021		Market Outperform → Market Perform	JMP Securities
8/23/2021	$22.00 → $18.50	Buy → Neutral	HC Wainwright & Co.